Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 9/20 | 1.00 |
| ▸ | HTR1A | P08908 | 9/20 | 0.76 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.76 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.76 |
| ▸ | ADRA1A | P35348 | 8/20 | 0.76 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.76 |
| ▸ | DRD3 | P35462 | 8/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.76 |
| ▸ | ADRA2A | P08913 | 7/20 | 0.76 |
| ▸ | DRD1 | P21728 | 7/20 | 0.76 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.76 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.76 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.76 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.76 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.76 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 6/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etymemazine SCHEMBL30627534 | 0.99 | CYP2D6 (0.98) | CYP2D6HTR1ACHRM2CHRM1ADRA1A | |
| Etymemazine SCHEMBL142535 | 0.99 | CYP2D6 (0.98) | CYP2D6HTR1ACHRM2CHRM1ADRA1A | |
| SCHEMBL11884951 | 0.88 | CYP2D6 (0.78) | CYP2D6HTR1ACHRM2CHRM1ADRA1A | |
| Methylpromazine SCHEMBL18994 | 0.87 | CHRM2 (1.00) | CYP2D6HTR1ACHRM2CHRM1ADRA1A | |
| Methylpromazine SCHEMBL18993 | 0.87 | CHRM2 (1.00) | CYP2D6HTR1ACHRM2CHRM1ADRA1A | |
| Methylpromazine SCHEMBL29354434 | 0.87 | CHRM2 (1.00) | CYP2D6HTR1ACHRM2CHRM1ADRA1A | |
| Methylpromazine SCHEMBL2774391 | 0.86 | CHRM2 (0.97) | CYP2D6HTR1ACHRM2CHRM1ADRA1A | |
| SCHEMBL2615384 | 0.85 | HTR1A (0.80) | CYP2D6HTR1ACHRM2CHRM1ADRA1A | |
| SCHEMBL6944155 | 0.85 | HTR1A (0.80) | CYP2D6HTR1ACHRM2CHRM1ADRA1A | |
| SCHEMBL13284571 | 0.84 | CHRM2 (0.78) | CYP2D6HTR1ACHRM2CHRM1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2014186623-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF A CHAGAS DISEASE | BIOMED VALLEY DISCOVERIES (US) | 2014-11-20 | — | — | WO | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1641446-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | Pediamed Pharmaceuticals, Inc. (US) | 2006-04-05 | — | — | EP | claimed |
| WO-2004112771-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | PEDIAMED PHARMACEUTICALS, INC. (US) | 2004-12-29 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | disclosed |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| WO-1996040084-A1 | COMPOSITIONS AND METHODS FOR USE OF PRESSURE SENSITIVE ADHESIVE TRANSDERMAL DEVICES CONTAINING A BIOADHESIVE HUMECTANT | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040086-A2 | COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5446070-A | Flexible, finite, bioadhesive, therapeutical agent in solid form | NOVER PHARMACEUTICALS, INC. (US) | 1995-08-29 | — | — | US | disclosed |
| EP-0540456-A1 | Alarm device for motor vehicles and motorbikes | COMET ELECTRONICA, S.A. (ES) | 1993-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | CYP2D6 953/4885HTR1A 3268/4885CHRM2 2534/4885 |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | ACE2, SARS1, ACE | CYP2D6 865/4885HTR1A 2774/4885CHRM2 2010/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | CYP2D6 865/4885HTR1A 3268/4885CHRM2 2594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.